Strongbridge Biopharma (NASDAQ:SBBP) has been given an average recommendation of “Buy” by the six ratings firms that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $14.67.

SBBP has been the subject of several research analyst reports. Cantor Fitzgerald set a $14.00 target price on Strongbridge Biopharma and gave the stock a “buy” rating in a research note on Thursday, April 5th. BidaskClub downgraded Strongbridge Biopharma from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, April 4th. HC Wainwright reiterated a “buy” rating and set a $18.00 target price on shares of Strongbridge Biopharma in a research note on Thursday, January 18th. Finally, Zacks Investment Research downgraded Strongbridge Biopharma from a “buy” rating to a “hold” rating in a research note on Wednesday, January 17th.

How to Become a New Pot Stock Millionaire

Shares of NASDAQ SBBP remained flat at $$8.15 during midday trading on Monday. The stock had a trading volume of 95,040 shares, compared to its average volume of 295,969. The company has a debt-to-equity ratio of -3.17, a current ratio of 4.88 and a quick ratio of 4.84. Strongbridge Biopharma has a one year low of $3.50 and a one year high of $9.25. The company has a market cap of $370.90, a P/E ratio of -5.66 and a beta of 0.97.

Strongbridge Biopharma (NASDAQ:SBBP) last issued its earnings results on Monday, March 12th. The biotechnology company reported ($0.34) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.34). The business had revenue of $2.98 million for the quarter, compared to the consensus estimate of $2.98 million. equities analysts predict that Strongbridge Biopharma will post -1.52 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Armistice Capital LLC boosted its stake in Strongbridge Biopharma by 69.4% in the 4th quarter. Armistice Capital LLC now owns 2,870,000 shares of the biotechnology company’s stock valued at $20,808,000 after purchasing an additional 1,175,400 shares during the period. Lyon Street Capital LLC boosted its stake in Strongbridge Biopharma by 239.0% in the 4th quarter. Lyon Street Capital LLC now owns 1,406,095 shares of the biotechnology company’s stock valued at $10,194,000 after purchasing an additional 991,322 shares during the period. BlackRock Inc. boosted its stake in Strongbridge Biopharma by 57.5% in the 4th quarter. BlackRock Inc. now owns 1,432,365 shares of the biotechnology company’s stock valued at $10,385,000 after purchasing an additional 522,875 shares during the period. Stonepine Capital Management LLC bought a new stake in Strongbridge Biopharma in the 4th quarter valued at $2,496,000. Finally, Broadfin Capital LLC boosted its stake in Strongbridge Biopharma by 10.4% in the 4th quarter. Broadfin Capital LLC now owns 3,186,695 shares of the biotechnology company’s stock valued at $23,104,000 after purchasing an additional 299,900 shares during the period. Institutional investors own 57.63% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Strongbridge Biopharma (SBBP) Receives Consensus Recommendation of “Buy” from Analysts” was first posted by Daily Political and is owned by of Daily Political. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://www.dailypolitical.com/2018/04/16/strongbridge-biopharma-sbbp-receives-consensus-recommendation-of-buy-from-analysts.html.

Strongbridge Biopharma Company Profile

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency in the United States and Canada.

Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.